Specifically focusing on these new antibodies (anti-Zo, Ks and Ha, plus anti-cN1A), a large study on 1194 ILD patients and 116 healthy controls evidenced a relatively high prevalence of such MSA, ranging from 0.9 to 2% [19]. Here, NT5C1A is linked to interstitial lung disease.